A large study of nearly 60,000 patients found that stage at diagnosis only partly explains the wide variation in lung cancer survival rates among different developed countries. Treatment differences also played a key role, with some countries experiencing lower survival rates due to delays in diagnosis or suboptimal staging.
This study found that SUVmax is a significant and clinically independent marker for progression-free survival in stage I non-small cell lung cancer (NSCLC) patients. The research included 95 medically inoperable patients who received stereotactic body radiation therapy (SBRT), with median overall survival of 25.3 months and progression...
A multi-center Phase III clinical trial demonstrates that Abraxane plus gemcitabine extends survival of late-stage pancreatic cancer patients compared to standard treatment. The study showed a 59 percent increase in one-year median survival rates and a doubling of two-year survival to 9%.
Researchers at Mayo Clinic identified an association between the naturally occurring enzyme Kallikrein 6 and malignant brain tumors. Higher levels of KLK6 were associated with shorter patient survival rates, but blocking its receptors made tumor cells more susceptible to treatment.
A study of 722 patients found that those taking beta-blockers for other conditions lived longer after receiving radiotherapy. The use of beta-blockers improved survival rates without disease spreading or recurring, but not locoregional progression-free survival.
A large-scale Swedish study has found that oesophageal cancer patients who undergo surgery by high-volume surgeons have a significantly lower long-term mortality rate. The study's main finding is that centralization to fewer surgeons results in better survival after esophageal cancer surgery.
A new study led by Johns Hopkins Medicine found that long-term survival rates for patients undergoing abdominal aneurysm repair with either open or less-invasive endovascular procedures are comparable. However, the research suggests that elderly patients may not benefit from the minimally invasive operation.
Pomalidomide, a new immunomodulatory drug, demonstrates significant increases in progression-free survival and overall survival for patients with relapsed and treatment-resistant multiple myeloma. The study found improved outcomes in both younger and older patients, offering a promising new option to extend survival.
Researchers found that statin use improved progression-free survival and disease-specific survival in patients with stage III inflammatory breast cancer. Patients who took hydrophilic statins saw the greatest improvement in survival, with an average of 4.88 years.
A study published in the Journal of Thoracic Oncology found that denosumab was associated with significantly improved overall median survival in lung cancer patients, including those with non-small-cell lung cancer and small-cell lung cancer. The treatment also showed improved survival in patients with squamous cell carcinoma.
A new study found that black patients with kidney cancer have a survival disadvantage compared to white patients, even when diagnosed at early stages or receiving less aggressive treatment. The study analyzed nearly 40,000 renal cell carcinoma patients and confirmed poorer survival rates for blacks.
Researchers found that radiation therapy significantly improved overall and breast cancer-specific survival rates for elderly women with early-stage ER-positive breast cancer. The study analyzed data from over 29,000 women and showed that radiation treatment increased median survival by nearly four years compared to surgery alone.
A study published in the Journal of Thoracic Oncology found that VeriStrat can predict response to erlotinib, but does not provide a survival benefit. The test showed a significant difference in median survival between good and poor responders, with good responders experiencing longer survival on erlotinib.
A six-gene signature has been identified that can predict survival in men with aggressive prostate cancer. The test uses blood samples and shows promise for determining the course of action for patients, clinical trial eligibility, and targeted studies.
A post-hoc analysis of the phase III MISSION trial suggests that patients with EGFR-mutant tumors may benefit from sorafenib, which showed improved progression-free survival and disease control rates. In contrast, median overall survival was similar between treatment groups.
Researchers found that adding bavituximab to docetaxel chemotherapy improves response rates, progression-free survival, and overall survival in late-stage non-squamous, non-small cell lung cancer (NS-NSCLC) patients. The study showed a doubling of the overall response rate compared to the control arm.
A study of 168 Stage III NSCLC patients found that married women had the best three-year survival rate of 46 percent, while single men had the worst rate of 3 percent. Married patients generally had improved survival rates compared to single patients, with 33 percent vs. 10 percent.
A recent study published in the University of Maryland Medical Center found that married lung cancer patients have a higher survival rate compared to single patients. The researchers believe that social support from spouses is a key factor contributing to improved survival rates for married lung cancer patients.
A study published in European Journal of Epidemiology found that cancer survival rates in Germany have aligned significantly since reunification. While there are still slight differences, they have decreased compared to the pre-reunification era.
A new study published in The Journal of Urology reports that PSA testing has led to improved survival rates for patients with newly diagnosed prostate cancer that has spread to the bones or other parts of the body. The disparity between African American and Caucasian men has been resolved, with African American men now having a compara...
A phase III clinical trial shows Enzalutamide extends life by five months, with significant survival benefits and reduced side effects compared to traditional chemotherapy. The study also reveals improved measures including PSA blood levels and progression-free survival.
The combination of anastrozole and fulvestrant improved overall survival and progression-free survival in postmenopausal women with hormone receptor-positive metastatic breast cancer. The study showed a six-month extended median survival time compared to anastrozole alone, and improved median time to disease progression.
Researchers at Henry Ford Hospital discovered that African Americans with throat cancer who are HPV positive have significantly better overall survival rates compared to those without HPV. The study also found that African Americans with late-stage oropharyngeal cancer who are HPV negative face a higher risk of death.
The study found that children with cancer were more likely to survive if they participated in clinical trials, particularly for rare tumours like hepatoblastoma. Between 1978 and 2005, the percentage of children enrolled in trials increased, leading to significant improvements in survival rates across various cancers.
A recent study found that patients who received chemotherapy following removal of periampullary cancer experienced improved overall survival compared to those who did not receive chemotherapy. The study also suggested that gemcitabine therapy provided the most significant survival benefit, with a median survival time of 43.1 months.
Researchers identified a genetic marker in the vitamin D receptor gene associated with improved overall survival rates among pancreatic cancer patients. The study's findings suggest that this genetic variation may play a role in the survival of patients treated for advanced pancreatic cancer.
A new blood test discovered circulating tumour cells can predict progression-free survival and overall survival in early-stage breast cancer patients. The presence of CTCs is associated with worse survival rates, but the correlation increases when concentrations are higher.
Climate conditions at nesting beaches affect early survival of turtle eggs and hatchlings, with warmer El Niño conditions linked to higher mortality rates. The study predicts a 50% drop in egg and hatchling survival by 2112 due to global climate change.
A new study from the UK shows that completion of pulmonary rehabilitation significantly improves survival in patients with chronic obstructive pulmonary disease (COPD). Patients who completed rehabilitation had a higher level of response in exercise capacity and a significant survival advantage compared to those who did not complete re...
A new study by Lawson Health Research Institute suggests that intensive kidney dialysis at home can lead to better survival rates, blood pressure results, and biochemical test values compared to conventional dialysis in clinics.
Researchers analyzed data from 4,168 Medicare beneficiaries with advanced non-small cell lung cancer aged 65 or older. They found no significant difference in overall survival between those treated with bevacizumab and those receiving standard chemotherapy alone. The study's findings suggest that bevacizumab should not be considered th...
A study by Dana-Farber Cancer Institute researchers found that adding bevacizumab to standard chemotherapy for non-small cell lung cancer in patients over 65 did not significantly increase survival rates. The treatment approach was previously approved by the FDA but failed to show substantial benefits.
Scientists discovered the Nurr1 gene plays a crucial role in neuron survival associated with synaptic activity. The findings provide insight into the relationship between early synaptic deficits and neurodegeneration in Alzheimer's disease.
A DNA repair pathway-focused score has been developed to predict chemotherapy response in ovarian cancer patients. The score is positively correlated with complete response rate, recurrence-free survival, and progression-free survival, and outperforms other clinical factors in predicting overall survival.
A phase II clinical trial showed encouraging survival in patients with stage 3B/4 non-small cell lung cancer (NSCLC) treated with belagenpumatucel-L. The median survival rate was 14.5 months, and the five-year survival rate was 20%. Patients with stable disease had a longer median survival of 44 months.
Research finds improved survival rates among patients with non-shockable cardiac arrests when given CPR based on updated guidelines. The likelihood of survival to discharge increased from 4.6% to 6.8%, and one-year survival doubled from 2.7% to 4.9%
A study by UCLA's Jonsson Comprehensive Cancer Center found that early Positron Emission Tomography (PET) response after neoadjuvant chemotherapy is associated with increased survival in patients with soft tissue sarcomas. Patients who showed a significant PET response had significantly longer survival rates compared to those who did not.
Patients with high-risk GI tumors who received imatinib for 3 years instead of 1 year had improved recurrence-free survival and overall survival. The study found that longer treatment with the cancer drug resulted in better survival outcomes and fewer patients discontinued treatment due to adverse effects.
Researchers at the University of Alberta discovered that some breast cancer tumors with weak 'survival' systems responded better to taxane chemotherapy than those with strong survival systems. This finding could lead to new strategies for identifying patients who may not respond to this common treatment.
A study by ecologists in New Zealand found that a 1170 km2 marine sanctuary significantly improved survival of Hector's dolphins, one of the rarest dolphin species. The research revealed a 5.4% increase in survival rates since the Marine Protected Area was designated in 1988.
The study reported a significant increase in five-year and 10-year survival rates for children with acute lymphoblastic leukemia, rising to 90.4% and 83.9%, respectively. Advances in treatment, including new drugs and supportive care, contributed to the improved outcomes.
The largest-ever study of childhood Acute Lymphoblastic Leukemia (ALL) reveals a remarkable improvement in the five-year survival rate, increasing from 83.7% in 1990-1994 to 90.4% in 2000-2005. This significant advancement is attributed to better treatment and drug optimization, not the introduction of new drugs.
A new study reveals that secondhand smoke results in graft rejection in transplant patients, with a specific enzyme's expression being key to the process. Researchers found that SHS suppressed an enzyme produced by innate immune cells, hindering long-term islet allograft survival.
Neuroscientist Joseph LeDoux suggests that studying animal survival instincts can provide insights into human emotions. By analyzing brain functions used for survival, researchers may gain new understandings of both humans' and animals' emotional responses.
A new melanoma drug, vemurafenib (Zelboraf), has been shown to nearly double the median overall survival of patients with metastatic melanoma. The Phase 2 trial found that 53% of patients responded to treatment and experienced improved survival rates.
A combination of guideline-recommended therapies for heart failure treatment significantly improved two-year survival rates. Adding each therapy incrementally increased the overall survival rate, with a maximum 83% reduction in mortality at four-to-five-therapy plateau.
Researchers at Ohio State University Comprehensive Cancer Center develop an oncolytic measles virus to treat disseminated human medulloblastoma. The treatment extended survival by 122% in a model of disseminated brain cancer, with treated animals surviving up to 82 days on average.
Research identifies SIRT1 as a key enzyme protecting leukemia stem cells from stress and driving cancer recurrence. Inhibiting SIRT1 selectively reduces CML stem cell survival and growth, offering a potential therapeutic target for treatment resistance.
A new immunotherapy for companion dogs with advanced-stage non-Hodgkin lymphoma improves survival by nearly four-fold, increasing median tumor-free survival by nine months. The treatment combination prolongs survival while maintaining quality of life.
A study found that women with invasive epithelial ovarian cancer and a BRCA gene mutation had improved 5-year overall survival, with BRCA2 carriers having the best prognosis. The study analyzed data from 26 observational studies and included 1,213 cases with pathogenic germline mutations in BRCA1 or BRCA2.
Researchers found that regorafenib slowed tumor progression and lengthened patient lives by 29% compared to placebo. The median survival time increased from 5 months to 6.5 months, with a 23% reduced risk of cancer-related death.
A University of Illinois study found that personalized prognostic tools and gene-based therapies can improve the survival and quality of life of glioblastoma patients. The researchers discovered new general and clinical-dependent gene profiles that can be used to predict patient outcomes and select targeted therapies.
Researchers found sorafenib to be effective in patients with non-small cell lung cancer and a KRAS mutation, achieving a 52.6% rate of no progression at six weeks. However, median overall survival was only 5.3 months, indicating unsatisfactory outcomes.
A nationwide study found demographic and clinical factors associated with Parkinson's disease survival. Dementia was diagnosed in 69.6% of the study population, particularly among black patients, and significantly increased mortality risk. Environmental exposures also seemed to influence survival rates.
Scientists at Thomas Jefferson University's Center for Translational Medicine have found that reducing N-cadherin levels in pancreatic cancer cells can slow down their mobility and prolong survival in mice by 25 percent. This discovery could lead to new targeted therapies for pancreatic cancer.
A systematic review and meta-analysis of randomized control trials found no improvement in overall survival for adult patients with advanced follicular lymphoma who received high-dose chemotherapy and ASCT compared to conventional-dose chemotherapy alone. The study concluded that HDC-ASCT is not effective as a primary treatment option.
The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer. Immediate zoledronic acid use also improved survival outcomes, particularly in women who were truly menopausal at diagnosis.
Researchers found that high levels of inflammation significantly shorten white dialysis patients' lives, but African Americans with similar inflammation levels survive similarly. A new study aims to understand and possibly mitigate this survival difference.
Researchers will collect cancer incidence data from 13 Appalachian states to identify differences in relative survival and avoidable death between sub-regions and non-Appalachian areas. The findings will inform the development of effective evidence-based cancer control interventions for the region.
A phase III trial found that concurrent chemo-radiotherapy significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma. The treatment regimen resulted in higher progression-free and distant metastasis-free survival rates compared to radiation alone.